Loading
Belgian maker of the Idylla molecular tests, one of which is the FDA companion diagnostic for nivolumab in MSI-high bowel cancer.
Biocartis is a privately held molecular diagnostics company headquartered in Mechelen, Belgium, built around its Idylla platform. Its Idylla CDx MSI Test was approved by the FDA in August 2025 as the companion diagnostic for nivolumab, alone or with ipilimumab, in microsatellite instability-high colorectal cancer.
A test that finds MSI-high bowel cancer, the group that can be treated with nivolumab alone or with ipilimumab.
Shares Companion diagnostics, Colorectal cancer.
Shares Companion diagnostics, Colorectal cancer.
Shares Idylla CDx MSI Test, Companion diagnostics, Colorectal cancer.
Shares Companion diagnostics, Colorectal cancer.
Shares Companion diagnostics, Colorectal cancer.
Shares Companion diagnostics, Colorectal cancer.
Shares Companion diagnostics, Colorectal cancer.
Shares Companion diagnostics, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/